NASDAQ:CYCN Cyclerion Therapeutics Q4 2025 Earnings Report $3.49 +0.13 (+3.87%) Closing price 09/8/2026Extended Trading$3.49 0.00 (0.00%) As of 09/8/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cyclerion Therapeutics EPS ResultsActual EPS-$1.33Consensus EPS -$2.66Beat/MissBeat by +$1.33One Year Ago EPSN/ACyclerion Therapeutics Revenue ResultsActual Revenue$1.03 millionExpected Revenue$0.10 millionBeat/MissBeat by +$925.00 thousandYoY Revenue GrowthN/ACyclerion Therapeutics Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCyclerion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Cyclerion Therapeutics Earnings HeadlinesKorsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 MillionSeptember 8, 2026 | globenewswire.comCyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s PipelineApril 21, 2026 | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 19 at 1:00 AM | Stansberry Research (Ad)Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?April 2, 2026 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)April 2, 2026 | prnewswire.comCyclerion to combine with Korsana Biosciences in $380 million merger dealApril 2, 2026 | msn.comSee More Cyclerion Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclerion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclerion Therapeutics and other key companies, straight to your email. Email Address About Cyclerion TherapeuticsCyclerion Therapeutics (NASDAQ:CYCN) was a clinical-stage biopharmaceutical company focused on developing medicines that target soluble guanylate cyclase (sGC), an enzyme involved in nitric oxide signaling. The company investigated sGC stimulators for diseases affecting the central nervous system, cardiovascular system and other organs. Cyclerion’s development programs included zagociguat (formerly CY6463), an oral sGC stimulator studied for central nervous system disorders, as well as praliciguat and olinciguat, which were investigated for conditions involving vascular and metabolic dysfunction. The company’s programs were primarily in clinical development rather than commercial production, and Cyclerion did not have an established portfolio of marketed products. Cyclerion was formed in 2019 through a spinout from Ironwood Pharmaceuticals and was headquartered in Cambridge, Massachusetts. Its operations and programs were focused on drug discovery and clinical development, with no broad geographic commercial presence reported. Publicly available information indicates that the company subsequently reduced or wound down its operations, so its historical pipeline should be distinguished from the activities of any successor or other entity holding rights to its programs.View Cyclerion Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
